Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $65 | $102 | $147 | $348 |
| Gross Profit | -$65 | -$102 | -$147 | -$348 |
| % Margin | – | – | – | – |
| R&D Expenses | $16,362 | $13,015 | $17,890 | $11,032 |
| G&A Expenses | $6,022 | $7,146 | $8,386 | $6,441 |
| SG&A Expenses | $6,022 | $7,146 | $8,386 | $6,441 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$674 |
| Operating Expenses | $22,384 | $20,161 | $26,276 | $17,473 |
| Operating Income | -$22,384 | -$20,161 | -$26,276 | -$17,473 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $136 | $605 | -$577 | $2,405 |
| Pre-Tax Income | -$22,248 | -$19,556 | -$26,853 | -$15,068 |
| Tax Expense | -$2,417 | -$1,800 | -$2,125 | -$1,801 |
| Net Income | -$19,831 | -$17,756 | -$24,728 | -$13,267 |
| % Margin | – | – | – | – |
| EPS | -2.08 | -1.87 | -3.17 | -2.95 |
| % Growth | -11.2% | 41% | -7.5% | – |
| EPS Diluted | -2.08 | -1.87 | -3.17 | -2.95 |
| Weighted Avg Shares Out | 9,551 | 9,503 | 7,797 | 4,503 |
| Weighted Avg Shares Out Dil | 9,551 | 9,503 | 7,797 | 4,503 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $135 | $5 | $250 | $0 |
| Depreciation & Amortization | $65 | $102 | $147 | $348 |
| EBITDA | -$22,183 | -$19,454 | -$26,706 | -$14,720 |
| % Margin | – | – | – | – |